1. Clinical characteristics of age-related macular degeneration (AMD) {#sec0005}
=====================================================================

Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss among the elderly, accounting for 8.7% of blindness worldwide. AMD is most prevalent in populations of European ancestry with approximately 1--3% of the total population suffering from an advanced form of AMD ([@bib0060], [@bib0445], [@bib0495]). Globally, the total number of patients with any type of AMD is expected to increase over the next 25 years to 288 million affected individuals ([@bib0495]).

The disease is characterized by a gradual loss of central vision due to photoreceptor cell degeneration in the centre of the retina at the back of the eye, known as the macula. Photoreceptors are in close contact with a layer of cells called the retinal pigment epithelium (RPE). RPE cells support the function of the photoreceptors and play an important role in maintaining retinal homeostasis. In AMD, this natural function of the RPE is disturbed, resulting in the accumulation of retinal waste products called drusen underneath the RPE. Drusen are the tell tale sign of AMD and are easily recognized by ophthalmologists.

AMD is a progressive retinal disease is which the early stage is characterized by relatively few small drusen within the macula. When AMD progresses, drusen size and number increase, eventually leading towards more advanced stages of AMD. Two forms of advanced AMD are distinguished. The first form, neovascular AMD, is characterized by infiltration of abnormal blood vessels into the retina. These newly formed vessels are fragile and when they break, the leakage of blood constituents in the retina leads to sudden vision loss. The second form of advanced AMD, geographic atrophy, is the result of gradual degeneration of the RPE and photoreceptors cells. Although neovascularization occurs in only 15--20% of AMD cases, it is responsible for the vast majority of vision loss caused by AMD. Drugs targeting vascular endothelial growth factor (VEGF), one of the central molecules in neovascularization, have proven to be very successful in neovascular AMD. However, no treatment is available for the remaining majority of early, intermediate or geographic atrophy AMD cases, and furthermore there are no effective means of preventing progression of early to advanced stages ([@bib0055], [@bib0225]).

2. The complement system plays a central role in the etiology of AMD {#sec0010}
====================================================================

2.1. Research on the etiology of AMD: a historical perspective {#sec0015}
--------------------------------------------------------------

Today it is known that AMD is the result of a complex interaction of environmental and genetic risk factors. Pooled evidence from numerous studies has demonstrated that environmental factors like aging itself, smoking behavior, and body mass index (BMI) are strong risk factors for AMD. In addition, cataract surgery, cardiovascular disease and family history are also strongly associated ([@bib0060]). Before any specific gene or biological pathway had been conclusively linked to AMD, studies into the molecular constituents of drusen had already suggested that AMD may have an immunological component. This suggestion arose after proteins involved in inflammation and/or other immune-associated responses, including components of the complement system, were found within drusen ([@bib0175], [@bib0235], [@bib0320]).

Evidence for a strong genetic component in AMD arose from twin and family studies. Twin studies observed a high concordance of AMD between monozygotic pairs, even double compared to dizygotic pairs, and estimated that the heritability of AMD may be as high as 45 to 70% ([@bib0190], [@bib0300], [@bib0410]). These findings were in line with familial aggregation analyses that observed a higher prevalence of AMD characteristics and an earlier onset of disease symptoms among relatives of patients compared to control families ([@bib0260], [@bib0400]).

2.2. Genetic evidence for a role of the complement system in AMD {#sec0020}
----------------------------------------------------------------

In search for genomic regions implicated in AMD, genetic linkage analyses were done in large family-based studies ([@bib0010], [@bib0220], [@bib0270], [@bib0405], [@bib0490]). Among a few other regions, the findings from these studies strongly and consistently implicated a region on chromosome 1 in the disease. When the first genome-wide association study (GWAS) for AMD was performed in 2005, it identified that same genomic region, which lead to the discovery of a highly associated genetic variant in complement factor H (*CFH*; Tyr402His) ([@bib0265]). These findings were corroborated by three additional studies ([@bib0105], [@bib0180], [@bib0185]).

Through genetic studies that followed over the next decade, the understanding of the genetic basis of AMD increased dramatically with the identification of disease-associated variants across several biological systems ([@bib0145]). The genetic link between AMD and the complement system was further expanded when genetic variants in or near complement factor I (*CFI)*, complement component 3 (*C3),* complement component 2 (*C2)*, complement component 9 (*C9*), complement factor B (*CFB)* and vitronectin (*VTN*) were also found to be associated with the disease ([@bib0110], [@bib0145], [@bib0155], [@bib0170], [@bib0275], [@bib0500]) ([Table 1](#tbl0005){ref-type="table"}). In addition, a common haplotype carrying a deletion of complement factor H related genes *CFHR1* and *CFHR3* was found to be protective for AMD ([@bib0215]).

2.3. The role of rare genetic variants in AMD {#sec0025}
---------------------------------------------

Common genetic variants (with a minor allele frequency (MAF) of \>5% in the population) near the complement genes *CFH*, *C2/CFB*, *C3* and *CFI* together explain 40--60% of the heritability of AMD ([@bib0150]). However, a large fraction of the heritability still remains unknown and is referred to as *missing heritability*. One hypothesis states that low frequency and rare genetic variants (with a MAF of \<1--5% and \<1%, respectively) may explain the remaining fraction of the heritability ([@bib0280]). During the past years, genetic studies in AMD have therefore shifted towards the identification of rare genetic variants. However, a practical problem arises when analyzing rare variants. The number of patients and controls needed for the identification of novel variants increases when variants are more rare, since the sample size requirements increase roughly linearly with the inverse of the allele frequency. Therefore, analyses of very large cohorts are required for a comprehensive understanding of the role of rare genetic variants in AMD.

2.4. Genetic approaches to identify rare genetic variants in AMD {#sec0030}
----------------------------------------------------------------

In order to discover rare variants investigators resort to other methods of analyses than those methods yielding insight into common variation. An effective approach that can be used to detect rare disease-associated variants is through a GWAS using exome chips. An exome chip is an array containing both common genetic variants as well as rare exonic variants, and is cost-effective in capturing a specific set of variants in large case-control studies. These chips can be customized and enriched for specific variants of interest. The approach is limited in the sense that it cannot discover new genetic variants other than the ones that the chip captures, but after imputation the chip covers over 12 million variants across the genome ([@bib0155]). A recent large GWAS using exome chips detected 52 (45 common and 7 rare) variants at 34 genomic regions that are independently associated with AMD. More than one third (19/52) of these variants reside in or near a gene of the complement system: *C2/CFB*, *C3*, *C9*, *CFH*, *CFI*, and *VTN* ([Table 1](#tbl0005){ref-type="table"}). Besides evaluating the association of single genetic variants with the disease, the cumulative number of rare variants detected across an entire gene can be compared between patients and control individuals using burden tests. Interestingly, a significant burden of rare variants in the *CFH* and *CFI* genes, in addition to two other genes (*TIMP3* and *SLC16A1*), was observed in AMD ([@bib0155]).

Another approach that is widely used to detect rare variants is sequence analysis of candidate genes in cases and controls. An advantage of this approach above the use of exome chips is that it can discover new genetic variants, thereby allowing a comprehensive analysis of all genetic variation in a candidate gene or a set of candidate genes. With the development of next-generation sequencing technologies, tens to hundreds of genes can effectively be analyzed in large cohorts consisting of thousands of individuals. The candidate gene approach has been successfully employed in AMD in several studies, which have mainly focused on sequencing of genes of the complement system and other genes previously associated with AMD. These studies lead to the discovery of rare variants in the *CFH*, *CFI*, *C3* and *C9* genes in AMD ([@bib0255], [@bib0415], [@bib0455], [@bib0465], [@bib0515]).

Whereas candidate gene sequencing is a very targeted approach, whole exome sequencing (WES) or whole genome sequencing (WGS) can interrogate genetic variants in all coding regions of the genome (WES) or even the entire genome (WGS). Since WES and WGS are expensive to perform in large cohorts, approaches can be used to enrich for rare variants, for example by analyzing large AMD families. Recent studies in AMD using WES and WGS have successfully identified novel genetic variants in AMD using a case-control cohort ([@bib0200]) or by analyzing multiple affected individuals of large AMD families ([@bib0100], [@bib0165], [@bib0205], [@bib0355], [@bib0360], [@bib0385], [@bib0510]). New genetic variants were detected in *CFH*, *CFI*, *C3* and *C9*, in addition to other genes (*FBN2* and *HMCN1*). Although rare variants segregated with AMD in some of these families ([@bib0355], [@bib0360], [@bib0510]), several variants did not perfectly segregate with the disease, but were enriched in cases compared to control individuals ([@bib0165], [@bib0205], [@bib0385]). This is in line with the complex etiology of AMD, to which both common and rare genetic variants, and also environmental factors contribute.

3. Rare genetic variants in the complement system {#sec0035}
=================================================

Multiple rare genetic variants in the complement system have been associated with AMD. The following paragraphs summarize these variants, focusing on the ones that were found in more than a single AMD patient. A complete list of rare variants described in literature is presented in Supplementary Table 1 and visualized in [Fig. 1](#fig0005){ref-type="fig"}.

3.1. Complement factor H {#sec0040}
------------------------

An important rare variant associated with AMD, *CFH* Arg1210Cys, was discovered after re-sequencing a rare risk haplotype in *CFH* ([@bib0365]). The authors demonstrated that the Arg1210Cys variant was highly associated with AMD, independently of the common variant Tyr402His. Moreover, carriers of this variant were significantly younger when the first symptoms of AMD appeared. The Arg1210Cys variant conferred a 47 times higher risk of developing AMD ([@bib0155]).

Earlier, nonsense variant Gln408Ter and missense variant Arg1078Ser in *CFH* had already been identified in families that presented with a particular subtype of AMD known as cuticular drusen. Here it was argued that the rare variant, in addition to the common variant *CFH* Tyr402His, may underlie the phenotype ([@bib0030]). In addition, in other families with cuticular drusen, frameshift variants Ile184Leufs\*33 and Lys204Thrfs\*26 were identified, also independently of *CFH* Tyr402His ([@bib0460]).

Splice site variant *CFH* c.790 + 1G \> A and coding variants *CFH* Arg53Cys, Asp90Gly, Arg127His, Arg175Pro, Arg175Gln, Cys192Phe, and Ser193Leu were identified by WES of AMD families in which known genetic risk factors could not explain the high burden of disease ([@bib0165], [@bib0485], [@bib0510]). Variant *CFH* Pro503Ala was identified using WES in an Amish family after exclusion of the other main risk variants for AMD, and was significantly associated with AMD in an Amish AMD case-control cohort ([@bib0205]) ([Table 2](#tbl0010){ref-type="table"}). Next-generation sequencing was performed for *CFH* in a cohort of 2417 individuals, demonstrating an enrichment of rare variants in functional domains of factor H in AMD. In this study, 65 coding *CFH* variants were identified of which only 15 rare variants were found in more than one affected individual; the other variants were found only in single cases ([Table 3](#tbl0015){ref-type="table"}, Supplementary Table 1) ([@bib0455]).

Overall, three different splice site variants, ten different nonsense, four different frameshift and 106 different rare missense variants in *CFH* were detected in AMD case-control and family studies (Supplementary Table 1). Functional variants seem to cluster in SCR 1-4 domains which mediate complement regulation of the protein, and SCR 19-20 which allow attachment of FH to the host cell. In total, 10 of 15 identified functional variants affect amino acid residues in one of these domains. In total, 124 variants were found of which 14 were significantly (p \< 0.05) associated with AMD ([Table 2](#tbl0010){ref-type="table"}). The majority of the coding variants (68/124) were found in only one study cohort and were not significantly associated with AMD.

3.2. Complement factor I {#sec0045}
------------------------

After sequencing the entire *CFI* gene in a subset of patients, and subsequent replication in a number of large case-control cohorts, the variant Gly119Arg was shown to be strongly associated with AMD ([@bib0465]). The Gly119Arg variant conferred a 5 times higher risk of developing AMD ([@bib0155]).

Additional variants in *CFI* have been identified in AMD families, including Gly188Ala ([@bib0465]), Leu131Arg ([@bib0165]), and Val412Met ([@bib0355]). It has been demonstrated that the *CFI* gene is enriched for rare variants four-fold in AMD cases compared to controls, and that these variants largely reside in the catalytic domain (residing in the serine protease domain) of the protein ([@bib0415]). Of the 70 variants identified in this study ([@bib0255]), eight coding variants were confirmed in five or more individuals, while the majority of variants were found only once (Supplementary Table 1). None of the variants were individually associated with AMD, although three variants showed a nominal association (*CFI* Pro553Ser, Arg406His and Ala240Gly) ([Table 2](#tbl0010){ref-type="table"}).

Overall, one splice site variant, seven different nonsense, and 86 different rare missense variants in *CFI* were detected in AMD case-control and family studies (Supplementary Table 1). The variants appear to cluster in the serine protease domain, with 42 of 94 identified variants affecting amino acid residues in this domain, which is in accordance with a previous report ([@bib0415]). Of these variants, 14 were significantly (p \< 0.05) associated with AMD ([Table 2](#tbl0010){ref-type="table"}).

3.3. Complement component 3 {#sec0050}
---------------------------

The Lys155Gln variant in *C3* was described to be associated with AMD independently by three studies ([@bib0200], [@bib0415], [@bib0515]). The Lys155Gln variant confers a 3 times higher risk of developing AMD ([@bib0155]).

In a sequencing study of all coding exons of the *C3* gene, four other C3 variants were identified: Lys65Gln, Arg161Trp, Arg735Trp and Ser1619Arg ([@bib0090]). All but Arg161Trp were found to be associated in the index cohort, but none of the rare variant associations were replicated in an independent cohort. The Arg735Trp and Ser1619Arg variants and two additional variants, Val619Met and Lys633Arg, were identified by next-generation sequencing of the *C3* gene in 1676 cases and 745 controls, but none of the variants were found to be significantly associated with AMD ([@bib0415]).

Overall, 71 different rare missense variants in *C3* were detected in AMD case-control and family studies (Supplementary Table 1). The variants that effect protein function are located at the first and second MG domains. Of these variants, four variants were significantly (p \< 0.05) associated with AMD ([Table 2](#tbl0010){ref-type="table"}). The majority (39/71) of variants were found in only one in one study cohort and were not significantly associated with AMD.

3.4. Complement component 9 {#sec0055}
---------------------------

Sequence analysis of the *C9* gene in 1676 cases and 745 controls demonstrated that the Pro167Ser variant confers an increased risk of developing AMD ([@bib0415]). The Pro167Ser variant was confirmed to confer risk of AMD in other cohorts as well ([@bib0385]), with a 1.7 times increased risk of developing AMD ([@bib0155]).

Sequence analysis of *C9* also identified 2 other variants, Met45Leu and Ile203Val, but these were not found to be significantly associated with AMD ([@bib0415]). In addition, variant Arg118Trp was identified in an AMD family with three affected siblings ([@bib0165]). The nonsense variant Arg95Ter has been associated with a reduced risk for advanced AMD but is a founder mutation of East Asian origin and extremely rare in European populations ([@bib0340]).

Overall, four nonsense, one frameshift and 15 different rare missense variants in *C9* were detected in AMD case-control and family studies (Supplementary Table 1). Of these variants, three were significantly (p \< 0.05) associated with AMD ([Table 2](#tbl0010){ref-type="table"}). The majority (16/20) of variants were found in one study cohort and were not significantly associated with AMD.

4. Functional implication of rare genetic variants {#sec0060}
==================================================

A genetic association provides statistical evidence that a particular variant is implicated in the disease, but if offers no insight into the molecular mechanisms that underlie and lead to the disease. To better understand this, the functional consequences of genetic variants on the complement system need to be investigated. Although the complement system acts locally, complement components or activation products can be detected systemically, for example in serum or plasma. In literature, several studies have described the expression of complement regulators and measurements of both complement components and activation products in AMD patients compared to controls. In addition, for some variants *in vitro* studies have been performed to examine their effect. In the next paragraphs we summarize the rare variants described in AMD literature, and detail their functional effects ([Table 3](#tbl0015){ref-type="table"}).

4.1. Complement factor H {#sec0065}
------------------------

Complement factor H (FH) is an inhibitor and plays a key role in the alternative pathway of the complement system. FH protects tissues by inhibiting the formation of excess C3 convertase through competition with factor B (FB) in the binding of C3b, and in addition promoting the decay of surplus C3 convertase.

The Arg1210Cys variant showed reduced binding to C3b, C3d and heparin but normal cofactor activity to factor I (FI) ([@bib0285], [@bib0390]). Through the introduction of a cysteine residue, Arg1210Cys forms covalent interactions with human serum albumin ([@bib0390]). It has been postulated that it is the albumin bound to FH rather than any functional defect of the protein itself that eventually disrupts FH function ([@bib0370]).

Variants Arg53Cys and Asp90Gly are both located within the first four domains of FH which are known to bind C3b, however only Arg53Cys showed minor decreased affinity to bind C3b ([@bib0510]). Independent of the C3b affinity, the variants strongly affected co-factor activity of FI. In addition, Arg53Cys disrupted decay accelerating activity and was shown to correlate to low C3 levels ([@bib0120], [@bib0425], [@bib0510]). Later, variants c.790 + 1G \> A, Arg127His, Arg175Pro and Cys192Phe were analyzed for levels of serum concentration, and all variants, except Arg127His, had reduced FH serum levels compared to a control group. The coding variants all shown impaired protein secretion ([@bib0015], [@bib0485]).

Variants can be grouped according to effect on the protein function. Type 1 mutations cause lower protein expression levels as a result of misfolding or degradation of the protein, in contrast to type 2 mutations that result in reduced functionality which is not necessarily reflected in protein levels. This distinction is also observed for variants found in *CFH*. Serum concentration of FH and C3 were measured in plasma samples of carriers of 5 *CFH* variants (Cys192Phe, Tyr277Ter, Cys431Ser, and two splice-site variants). For these variants, lower FH concentrations were observed in each of the carriers compared to a non-carrier control set ([@bib0455]), and can thus be classified as type 1 mutations. For two other variants, Arg175Gln and Ser193Leu, serum levels were normal but these variants exhibited a reduced ability to degrade C3b ([@bib0165]), suggesting that they are type 2 mutations.

4.2. Complement factor I {#sec0070}
------------------------

Complement factor I (FI) is a serum serine protease that converts C3b and C4b to their inactive form to reduce the formation of the C3 and C5 convertases. Unbound C3b would otherwise result in increased C3 convertase formation and feedback amplification of the alternative pathway.

Overall, many rare variants in *CFI* result in lower FI levels in serum and consequently lower the regulatory activity of the alternative pathway ([@bib0255], [@bib0415]). Serum measurements found low FI levels for pathogenic variants Ala240Gly and Gly119Arg compared to non-carriers, while serum levels were normal for Pro553Ser and Arg406His ([@bib0255]).

In an independent study, *CFI* Gly119Arg and Gly188Ala resulted in reduced FI levels in plasma, which was supported by *in vitro* analysis of recombinant FI in human cells, showing that mutant FI is expressed and secreted at lower levels than wild-type FI ([@bib0465]). Overall plasma samples of carriers of the Gly119Arg variant showed a lower ability to degrade C3b compared to non-carriers, but the ability of recombinant Gly119Arg mutant protein to cleave C3b and C4b was intact. This suggests that this variant is a type 1 mutation and that low expression levels underlie the observed functional effect ([@bib0465]). Similarly, variant Leu131Arg in *CFI* showed both impaired FI levels and an inability to properly cleave C3b ([@bib0165]), supporting that is also a type 1 mutation. A difficult variant to classify is *CFI* Pro553Ser, which confers risk for AMD in multiple studies ([@bib0165], [@bib0255]). The variant however does not alter system FI levels, is classified by prediction software as benign, and showed a lower ability to degrade C3b compared to non-carriers controls but not non-carriers cases.

4.3. Complement component 3 {#sec0075}
---------------------------

Complement factor 3 (C3) is the central player in the activation of the complement system and several rare variants in *C3* have been investigated functionally ([Table 3](#tbl0015){ref-type="table"}).

The C3 Lys155Gln variant is located close to the binding site for FH, and its interaction was analyzed both *in silico* and *in vitro* with matching results. The Lys155Gln variant causes inefficient binding of C3 with FH and consequently reduces cofactor mediated cleavage of C3b ([@bib0305], [@bib0415]). Variant Lys65Gln leads to a decreased binding of FH to C3b and a slightly lowered affinity to the membrane cofactor protein (MCP; also known as CD46). The Arg161Trp variant increases the affinity to bind to FB and thereby creates an overactive C3 convertase accompanied by increased formation of C3a, C5a and C5b-C9. In addition, Arg161Trp also has reduced binding affinities for MCP and FH, which would otherwise both inactivate C3b/C4b through co-factor activity with FI ([@bib0380], [@bib0395], [@bib0470]). Variant Arg735Trp demonstrated normal MCP, FB, sCR1 and FH binding and proper cleavage by FI ([@bib0140]).

4.4. Complement component 9 {#sec0080}
---------------------------

Complement factor 9 (C9) takes part in the formation of the terminal complement complex (TCC) comprised of several C5b-9 elements. The TCC can be soluble or it can form a scaffold on the surface of the membrane together with multiple (up to 16) C9 proteins to assemble a pore-like structure known as the membrane attack complex (MAC) promoting cell lysis.

Recently it was shown that carriers of the C9 Pro167Ser variant, associated with an increased risk for AMD, have elevated C9 concentrations in serum compared to non-carriers. It was hypothesized that increased C9 levels could result in elevated complement activation which, through lysis of the cells, may contribute to the degenerative process observed in AMD ([@bib0165]). Asian Founder mutation *C9* Arg95Ter is responsible for most Japanese C9 deficiency cases but is simultaneously protective for AMD. It is shown that C9 serum concentrations are low, even below detection level ([@bib0160], [@bib0210]), suggesting that less MAC can be formed which could otherwise contribute to retinal damage.

5. Complement therapies in AMD {#sec0085}
==============================

The treatment of neovascular AMD has highly improved with the introduction of anti-neovascularization therapy with VEGF as the principle target. However, VEGF-based treatment is not effective or even not applicable in most AMD patients since only a minority of patients suffer from the neovascular form of AMD. Currently, no available treatment is available for the majority of AMD patients that suffer from early or intermediate AMD or geographic atrophy. Moreover, no effective means other than a modest effect of AREDS supplements to reduce the risk of AMD progression is available ([@bib0005], [@bib0080], [@bib0075]). Because of the central role of the complement system in AMD, complement inhibition has been considered a potential therapeutic option and several clinical trials have been initiated to investigate this possibility ([Table 4](#tbl0020){ref-type="table"}) ([@bib0375], [@bib0475], [@bib0505]).

Of the studies that published the outcomes, the COMPLETE study was a phase II clinical trial with systemic eculizumab, an humanized IgG antibody that inhibits complement component 5 (C5). The trial results showed that eculizumab was not effective in the treatment of geographic AMD, as the growth of atrophic lesions did not decrease after 6 months of treatment ([@bib0505]). The MAHALO study was a phase II clinical trial with lampalizumab, an antibody directed against complement factor D. MAHALO showed promising preliminary results: progression of the geographic atrophy lesion showed a 20% reduction after 18 months of treatment and it was suggested that lampalizumab is most effective in a subpopulation of patients, since an even higher reduction rate was seen in patients carrying a specific *CFI* genotype ([@bib0375], [@bib0475]). A phase III trial with lampalizumab is currently ongoing, which will further investigate the role of the *CFI* genotype on treatment response.

In summary, a number of clinical trials using complement inhibitors in AMD have been performed, or are currently still running. Eculizumab seemed not to be effective, while lampalizumab may have a (limited) beneficial effect in reducing AMD progression.

6. Discussion and conclusion {#sec0090}
============================

Just over a decade after the initial discovery of the involvement of *CFH* in AMD ([@bib0265]), basic science has been translated to experimental approaches where complement inhibitors against AMD are now tested in clinical trials. Although the involvement of the complement system in AMD has been firmly established, the limited success of these clinical trials seem to suggest that the drugs currently tested are not entirely effective in the overall study populations ([@bib0475]). In part this may be explained by the fact that, besides the complement system, also other biological systems like the extracellular matrix, lipid homeostasis or oxidative stress may contribute substantially to AMD pathogenesis ([@bib0005], [@bib0155], [@bib0430]). At this time, it is not well understood how these pathways interact with each other in the development of the disease. Therefore the complement system is not necessarily the only, or even an appropriate target for any given AMD patient.

It is conceivable that a subset of patients would benefit more from anti-complement therapy than others, in particular those that have a genetic defect in genes of the complement system. It has now been shown that rare genetic variants in complement genes that are genetically associated with AMD often negatively impact the functioning of this system ([@bib0165], [@bib0255], [@bib0455], [@bib0465], [@bib0510]). However, does this mean that all AMD patients carrying a rare variant in the complement system will benefit from complement inhibitors?

Several issues arise when considering the role of rare variants in AMD. To date only few rare variants have been consistently replicated across multiple cohorts ([@bib0155], [@bib0200], [@bib0365], [@bib0415], [@bib0465], [@bib0515]). While some rare variants are present relatively abundantly in one population, they are virtually absent in other populations, for example Arg1210Cys in *CFH* ([@bib0095], [@bib0310], [@bib0365], [@bib0515]) and Gly119Arg in *CFI* ([@bib0020], [@bib0070], [@bib0255], [@bib0465]).

Many other potentially interesting variants have been found, illustrated by this review, but very large cohorts are required to detect a significant genetic association with AMD ([@bib0280], [@bib0295]). The question arises whether a rare variant is or is not relevant in the context of the disease if it cannot be genetically associated with AMD. Functional assays could help clarify if a genetic variant has an impact on protein stability or systemic levels. This may provide functional evidence that a variant could be involved in the pathogenesis of the disease in the cases where statistical tests are underpowered to detect any association.

At this time, patients who carry AMD-associated rare variants proven to have a negative impact on function, could be prioritized in clinical trials with complement inhibitors. Across multiple cohorts, numerous of such patients have now been identified. Such focused studies would offer a proof of principle that could later benefit many more patients that have a defective complement system based on functional tests, but carry genetic variants that are too rare to be statistically associated with AMD.

AMD patients should therefore be screened using a functional complement assay in addition to genetic analyses. An exciting future lies ahead in the field of AMD where, for each individual patient, genetic evidence and functional tests come together in a treatment plan that is personalized and tailored to the specific needs and requirements of that patient.

Appendix A. Supplementary data {#sec0100}
==============================

The following is Supplementary data to this article:

The authors would like to thank the International Age-Related Macular Degeneration Genomics Consortium (IAMDGC) for sharing minor allele frequencies and odd-ratio\'s of rare variants in the *CFH*, *CFI*, *C3* and *C9* genes identified in Fritsche et al 2016, and A. Kwong, X. Zhan, A. Swaroop and G.R. Abecasis for sharing their dataset of rare variants in the *CFH*, *CFI* and*C3*genes identified in Zhan et al. 2013. The research leading to these results has received funding from the European Research Council under the European Union\'s Seventh Framework Programme (FP/2007-2013)/ERC Grant Agreement n. 310644 (MACULA).

Supplementary data associated with this article can be found, in the online version, at [http://dx.doi.org/10.1016/j.molimm.2016.11.016](10.1016/j.molimm.2016.11.016){#intr0025}.

![Rare coding variants in *CFH*, *CFI*, *C3* and *C9* found in AMD patients.\
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###### 

Genes in the complement system associated with AMD.

Table 1

  Gene/Locus      Approach                      Reference[a](#tblfn0005){ref-type="table-fn"}
  --------------- ----------------------------- -------------------------------------------------------------------
  *C2/CFB*        Candidate gene                [@bib0170]
  *C3*            Candidate gene/WGS            [@bib0275] and [@bib0500])/([@bib0200], [@bib0415] and [@bib0515]
  *C9*            Candidate gene                [@bib0340] and [@bib0415]
  *CFH*           Candidate gene/Linkage/GWAS   [@bib0105], [@bib0180], [@bib0185] and [@bib0265]/[@bib0365]
  *CFHR1-CFHR3*   Candidate gene                [@bib0215]
  *CFI*           Candidate gene                [@bib0110]/[@bib0465]
  *VTN*           GWAS                          [@bib0155]

Reference of first cited association based on common and/or rare genetic variant.

###### 

Rare variants in complement genes associated with AMD and accompanying OR/LOD scores.

Table 2

  ----------------------------------------------------------------------------------------------------------------------------------
  Gene    Variant      Effect (Odds Ratio)   Significance (P-value and/or LOD score)                     Study
  ------- ------------ --------------------- ----------------------------------------------------------- ---------------------------
  *CFH*   Arg2Thr      Risk (14.08)          P = 0.0158[\*\*](#tblfn0015){ref-type="table-fn"}           [@bib0155]

  *CFH*   Arg53Cys     Risk (22.54)          LOD score 5.07, P = 6.7 × 10^−7^\                           [@bib0510] and [@bib0155]
                                             P = 0.00118[\*\*](#tblfn0015){ref-type="table-fn"}          

  *CFH*   Arg53His     Risk (13.39)          P = 0.01[\*\*](#tblfn0015){ref-type="table-fn"}             [@bib0155]

  *CFH*   Ser58Ala     Risk (2.82)           P = 0.00702[\*\*](#tblfn0015){ref-type="table-fn"}          [@bib0155]

  *CFH*   Asp90Gly     Risk                  LOD score 1.22, P = 0.009                                   [@bib0510]

  *CFH*   Arg175Gln    Risk (1.50)           P = 0.04                                                    [@bib0165]

  *CFH*   Ser193Leu    Risk                  P = 0.01                                                    [@bib0165]

  *CFH*   Ile221Val    Risk (11.80)          P = 0.0314[\*\*](#tblfn0015){ref-type="table-fn"}           [@bib0155]

  *CFH*   Arg303Trp    Risk (12.25)          P = 0.0378[\*\*](#tblfn0015){ref-type="table-fn"}           [@bib0155]

  *CFH*   Pro503Ala    Risk                  P = 9.27 × 10^−13^                                          [@bib0205]

  *CFH*   Gln950His    Protective (0.72)     P = 0.00258[\*\*](#tblfn0015){ref-type="table-fn"}          [@bib0155]

  *CFH*   Asn1050Tyr   Protective (0.36)     P = 5.92 × 10^−44^[\*\*](#tblfn0015){ref-type="table-fn"}   [@bib0155]

  *CFH*   Asn1056Lys   Protective (0.08)     P = 0.024[\*\*](#tblfn0015){ref-type="table-fn"}            [@bib0155]

  *CFH*   Arg1210Cys   Risk (31.8)           P = 3.2 × 10^−31^[\*](#tblfn0010){ref-type="table-fn"}      [@bib0155]

  *CFI*   Gly119Arg    Risk (3.87)           P = 8.6 × 10^−11^[\*](#tblfn0010){ref-type="table-fn"}      [@bib0155]

  *CFI*   Leu131Arg    Risk                  P = 0.02                                                    [@bib0165]

  *CFI*   Val152Met    Risk (7.57)           P = 4.65 × 10^−4^[\*\*](#tblfn0015){ref-type="table-fn"}    [@bib0155]

  *CFI*   Gly162Asp    Risk (20.29)          P = 0.00231[\*\*](#tblfn0015){ref-type="table-fn"}          [@bib0155]

  *CFI*   Arg187Ter    Risk (13.63)          P = 0.0175[\*\*](#tblfn0015){ref-type="table-fn"}           [@bib0155]

  *CFI*   Thr203Ile    Risk (2.46)           P = 0.0344[\*\*](#tblfn0015){ref-type="table-fn"}           [@bib0155]

  *CFI*   Ala240Gly    Risk (7.43)           P = 0.02                                                    [@bib0255]

  *CFI*   Ala258Thr    Risk (3.88)           P = 6.25 × 10^−5^[\*\*](#tblfn0015){ref-type="table-fn"}    [@bib0155]

  *CFI*   Gly287Arg    Risk (4.61)           P = 0.00761[\*\*](#tblfn0015){ref-type="table-fn"}          [@bib0155]

  *CFI*   Ala300Thr    eRisk (2.67)          P = 0.0144[\*\*](#tblfn0015){ref-type="table-fn"}           [@bib0155]

  *CFI*   Arg317Trp    Risk (12.20)          P = 1.97 × 10^−4^[\*\*](#tblfn0015){ref-type="table-fn"}    [@bib0155]

  *CFI*   Arg339Gln    Risk (11.83)          P = 0.0312[\*\*](#tblfn0015){ref-type="table-fn"}           [@bib0155]

  *CFI*   Arg406His    Protective (0.10)     P = 0.02                                                    [@bib0255]

  *CFI*   Val412Met    Risk                  LOD score 2.51                                              [@bib0355]

  *CFI*   Pro553Ser    Risk (3.7; 2.69)      P = 0.04; P = 0.03                                          [@bib0165] and [@bib0255]

  *C3*    Lys155Gln    Risk (3.12)           P = 1.5 × 10^−32^[\*](#tblfn0010){ref-type="table-fn"}      [@bib0155]

  *C3*    Arg161Trp    Risk                  P = 0.01                                                    [@bib0165]

  *C3*    Val619Met    Risk (2.66)           P = 2.38 × 10^−4^[\*\*](#tblfn0015){ref-type="table-fn"}    [@bib0155]

  *C3*    Arg1532Trp   Risk (12.29)          P = 0.0379[\*\*](#tblfn0015){ref-type="table-fn"}           [@bib0155]

  *C9*    Arg116Ter    Protective (0.20)     P = 0.021                                                   [@bib0340]

  *C9*    Arg118Trp    Risk (1.12)           OR = 0.04                                                   [@bib0165]

  *C9*    Pro167Ser    Risk (1.79)           P = 1.6 × 10^−14^[\*](#tblfn0010){ref-type="table-fn"}      [@bib0155]
  ----------------------------------------------------------------------------------------------------------------------------------

IAMDGC genome-wide significant, Locus-wide conditioned analysis (adjusting for the identified index variant(s) in the locus).

Did not reach genome-wide significance, p \< 0.05, Not conditioned for index variant(s) in the locus.OR = Odds-ratio, LOD = logarithm of the odds.

###### 

Described functional effects of rare variants in the complement system.

Table 3

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene                         Variant                                                                                                                                                                                                                                                                                                                                                                                                  Functional implication                                                                                                                                                                                                                                                                                Sources
  ---------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------
  *CFH*                        **Arg53Cys**                                                                                                                                                                                                                                                                                                                                                                                             Reported to possibly affect the local conformation of FH. This variant did not affect levels of FH in serum of 22 individuals, but showed slightly reduced binding affinity to C3b compared to wild type. Marked loss of decay accelerating activity. Trend towards lower cofactor activity for FI.   [@bib0510]

  Arg53His                     Like the 53Cys variant, the 53His variant showed minor decreased affinity to bind C3b. Independent of the C3b affinity, the variant strongly affected co-factor activity of FI. In addition, the variant disrupted decay accelerating activity and was shown to correlate to low C3 levels.                                                                                                              [@bib0230] and [@bib0345]                                                                                                                                                                                                                                                                             

  **Asp90Gly**                 No reported effect on FH levels in serum from 22 individuals. No effect on C3b binding affinity and decay accelerating activity. Significantly reduced cofactor activity for FI                                                                                                                                                                                                                          [@bib0510]                                                                                                                                                                                                                                                                                            

  **Arg127His**                Reduced FH serum levels in heterozygous and homozygous carriers and no secretion of the protein.                                                                                                                                                                                                                                                                                                         [@bib0015], [@bib0125] and [@bib0485]                                                                                                                                                                                                                                                                 

  **Arg175Pro**                Reduced FH serum levels and no secretion of the recombinant protein.                                                                                                                                                                                                                                                                                                                                     [@bib0485]                                                                                                                                                                                                                                                                                            

  **Arg175Gln**                No reported effect on FH levels. Reduced C3b degradation ability.                                                                                                                                                                                                                                                                                                                                        [@bib0165]                                                                                                                                                                                                                                                                                            

  **Cys192Phe**                Lower expression of FH and reduced secretion of the protein. Normal C3 in plasma of one carrier                                                                                                                                                                                                                                                                                                          [@bib0455] and [@bib0485]                                                                                                                                                                                                                                                                             

  **Ser193Leu**                No reported effect on FH levels. Reduced C3b degradation ability.                                                                                                                                                                                                                                                                                                                                        [@bib0165]                                                                                                                                                                                                                                                                                            

  Tyr277Ter                    Lower expression of FH and normal C3 in plasma of one carrier                                                                                                                                                                                                                                                                                                                                            [@bib0455]                                                                                                                                                                                                                                                                                            

  Arg303Gln                    Normal plasma levels for FH, FI and C3                                                                                                                                                                                                                                                                                                                                                                   [@bib0115]                                                                                                                                                                                                                                                                                            

  Gln400Lys                    Lower FH levels, but no effect on plasma concentrations of C3 and FB                                                                                                                                                                                                                                                                                                                                     [@bib0085]                                                                                                                                                                                                                                                                                            

  Cys431Ser                    Lower expression of FH and normal C3 in plasma of one carrier                                                                                                                                                                                                                                                                                                                                            [@bib0455]                                                                                                                                                                                                                                                                                            

  Val609Asp                    Affects FH expression and resulted in decreased alternative pathway activity and C3 level in remission                                                                                                                                                                                                                                                                                                   [@bib0440]                                                                                                                                                                                                                                                                                            

  Ser890Ile                    The variant did not result is differences in FH co-activity with FI. The C3b binding was not affected and FH concentration in plasma were normal. In addition a hemolytic assay showed that the capacity to regulate the alternative pathway on cellular surfaces was normal.                                                                                                                            [@bib0450]                                                                                                                                                                                                                                                                                            

  Gln950His                    This variant demonstrated reduced erythrocyte binding and, consequently, increased lysis after serum addition to sheep erythrocytes. Patient plasma levels of FH were not different compared to controls, but transient expression levels of mutant lagged behind that of the wild type. No impaired cofactor binding for FI was observed and normal complementary inhibitory functions were observed.   [@bib0315] and [@bib0440]                                                                                                                                                                                                                                                                             

  Thr956Met                    No effect on C3 or FH levels in plasma. The lysis of erythrocytes was not increased and no effect on protein expression was shown.                                                                                                                                                                                                                                                                       [@bib0350] and [@bib0440]                                                                                                                                                                                                                                                                             

  Val1007Leu                   No differences in FH co-activity nor C3b binding; normal hemolytic assay (capacity to regulate the alternative pathway on cellular surfaces); normal FH in plasma                                                                                                                                                                                                                                        [@bib0450]                                                                                                                                                                                                                                                                                            

  Asn1050Tyr                   Abnormal C3 and normal FH levels in serum                                                                                                                                                                                                                                                                                                                                                                [@bib0435]                                                                                                                                                                                                                                                                                            

  Gln1076Glu                   Normal C3 and FH levels in serum                                                                                                                                                                                                                                                                                                                                                                         [@bib0325]                                                                                                                                                                                                                                                                                            

  Gly1194Asp                   Slightly increased complement regulatory function of mutant FH on cell surfaces (sheep erythrocyte lysis); normal C3 FH and FI levels in serum                                                                                                                                                                                                                                                           [@bib0040] and [@bib0240]                                                                                                                                                                                                                                                                             

  Val1197Ala                   Normal lysis of sheep erythrocytes, low FH and C3 levels, and shows low binding to surface bound C3b.                                                                                                                                                                                                                                                                                                    [@bib0195] and [@bib0390]                                                                                                                                                                                                                                                                             

  Arg1203Trp                   Hemolytic test showed no lysis                                                                                                                                                                                                                                                                                                                                                                           [@bib0440]                                                                                                                                                                                                                                                                                            

  **Arg1210Cys**               This variant results in a covalent binding to human serum albumin which hampers all FH functional domains. It also shows reduced binding to heparin and endothelial cells and binding to C3b and C3d is also decreased. No effects on cofactor activity for FI was reported and no effect on erythrocyte lysis was shown.                                                                                [@bib0130], [@bib0245], [@bib0285], [@bib0370] and [@bib0390]                                                                                                                                                                                                                                         

  244 + 2T \> C\               Normal expression of FH and high C3 in plasma of one carrier                                                                                                                                                                                                                                                                                                                                             [@bib0455]                                                                                                                                                                                                                                                                                            
  splice site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  790 + 1G \> A; splice site   Lower expression of FH in three carriers and low C3 in plasma of one carrier                                                                                                                                                                                                                                                                                                                             [@bib0455] and [@bib0485]                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  *CFI*                        Pro50Ala\                                                                                                                                                                                                                                                                                                                                                                                                Elevated FB in plasma; normal C3 and FI in plasma; impaired function towards degradation of the alpha-chains of C4b and C3b in solution when FH was used as cofactor                                                                                                                                  [@bib0025]
                               (Pro32Ala)\*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  **Gly119Arg**\               This variant resulted in reduced FI levels in human serum as well as in transient *in vitro* expression studies. The variant resulted in a lower ability to degrade C3b due to impaired expression and secretion of the mutant protein.                                                                                                                                                                  [@bib0465], [@bib0165] and [@bib0255]                                                                                                                                                                                                                                                                 
  **(Gly101Arg)\***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **Leu131Arg**\               The variant resulted in a lower ability to degrade C3b which could be due to impaired expression and secretion of the mutant protein.                                                                                                                                                                                                                                                                    [@bib0165]                                                                                                                                                                                                                                                                                            
  **(Gly113Arg)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  **Gly188Ala**\               This variant resulted in lower FI levels in human serum as well as in transient *in vitro* expression studies. The variant resulted in impaired degradation of C3b.                                                                                                                                                                                                                                      [@bib0465]                                                                                                                                                                                                                                                                                            
  **(Gly170Ala)\***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Arg202Ile\                   This variant had no effect on FI levels in human serum                                                                                                                                                                                                                                                                                                                                                   [@bib0255]                                                                                                                                                                                                                                                                                            
  (Arg184Ile)\*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  **Ala240Gly**\               This variant resulted in lower or normal FI levels in human serum/plasma. The degradation of fluid phase C4b and C3b was normal, although the ability to cleave surface-bound C3b was impaired.                                                                                                                                                                                                          [@bib0045], [@bib0255] and [@bib0335]                                                                                                                                                                                                                                                                 
  **(Ala222Gly)\***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Gly261Asp\                   No effect on FI levels in human serum; slightly different migration pattern; normal degradation of C3b and C4b.                                                                                                                                                                                                                                                                                          [@bib0250], [@bib0255] and [@bib0330]                                                                                                                                                                                                                                                                 
  (Gly243Asp)\*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Thr300Ala\                   No effect on FI levels in human serum                                                                                                                                                                                                                                                                                                                                                                    [@bib0255]                                                                                                                                                                                                                                                                                            
  (Thr282Ala)\*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Arg317Trp\                   Normal FI plasma level and normal functioning on hemolytic assay; only impaired secretion compared to wildtype FI                                                                                                                                                                                                                                                                                        [@bib0045], [@bib0250] and [@bib0335]                                                                                                                                                                                                                                                                 
  (Arg299Trp)\*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Arg339Gln\                   Reduced C3, FH, and FB levels, but normal FI levels in serum                                                                                                                                                                                                                                                                                                                                             [@bib0440]                                                                                                                                                                                                                                                                                            
  (Arg321Gln)\*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Ile340Thr\                   Normal FI and C3 levels in serum                                                                                                                                                                                                                                                                                                                                                                         [@bib0040]                                                                                                                                                                                                                                                                                            
  (Ile323Thr)\*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Tyr369Ser\                   Normal FH and C4 levels; low C3 levels in serum                                                                                                                                                                                                                                                                                                                                                          [@bib0065]                                                                                                                                                                                                                                                                                            
  (Ile351Thr)\*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  **Arg406His**\               No effect on FI levels in human serum                                                                                                                                                                                                                                                                                                                                                                    [@bib0255]                                                                                                                                                                                                                                                                                            
  **(Arg388His)\***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Ile416Leu\                   Low FI and C3 serum levels; normal FB levels                                                                                                                                                                                                                                                                                                                                                             [@bib0025] and [@bib0420]                                                                                                                                                                                                                                                                             
  (Ile398Leu)\*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  His418Leu\                   Homozygous variation results in FI deficiency (low or undetectable FI and C3 levels)                                                                                                                                                                                                                                                                                                                     [@bib0480]                                                                                                                                                                                                                                                                                            
  (His400Leu)\*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Lys441Arg\                   This variant had no effect on FI levels in human serum                                                                                                                                                                                                                                                                                                                                                   [@bib0050] and [@bib0255]                                                                                                                                                                                                                                                                             
  (Lys423Arg)\*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Tyr459Ser\                   Normal FI and C3 levels in serum                                                                                                                                                                                                                                                                                                                                                                         [@bib0025]                                                                                                                                                                                                                                                                                            
  (Tyr441Ser)\*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Arg474Gln\                   Normal FI protein level.                                                                                                                                                                                                                                                                                                                                                                                 [@bib0440]                                                                                                                                                                                                                                                                                            
  (Arg456Gln)\*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Arg474Ter\                   Low FI and C3 serum levels; normal FB levels                                                                                                                                                                                                                                                                                                                                                             [@bib0025], [@bib0135] and [@bib0335]                                                                                                                                                                                                                                                                 
  (Arg456Ter)\*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  **Pro553Ser**\               This variant had no effect on FI levels in human serum and slightly lower ability to degrade C3b.                                                                                                                                                                                                                                                                                                        [@bib0165] and [@bib0255]                                                                                                                                                                                                                                                                             
  **(Pro535Ser)\***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  *C3*                         **Lys65Gln**\                                                                                                                                                                                                                                                                                                                                                                                            This variants weakened the interaction of C3b and FH and showed reduced MCP binding affinity                                                                                                                                                                                                          [@bib0395] and [@bib0470]
                               **(Lys43Gln)\***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  **Lys155Gln**\               This variant resulted in significantly reduced cleavage of C3b in fluid phase cofactor assays as well as reduced binding to FH. MCP cofactor activity was not changed.                                                                                                                                                                                                                                   [@bib0155], [@bib0200], [@bib0415] and [@bib0515]                                                                                                                                                                                                                                                     
  **(Lys131Gln)\***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **Arg161Trp**\               Reduced binding activity of C3b to FH in one study and no effect on binding and cleavage of C3 in other studies. MCP binding was reduced, FB binding was increased. This variant is discussed to be a gain-of-function variant of the convertase complex and C3a, C5a, C5b-9 formation was shown to be increased.                                                                                        [@bib0165], [@bib0290], [@bib0380], [@bib0395] and [@bib0470]                                                                                                                                                                                                                                         
  **(Arg139Trp)\***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **Arg735Trp**\               This variant showed no functional effects on MCP binding, FI cofactor activity, FB binding, CR1 binding and FH binding.                                                                                                                                                                                                                                                                                  [@bib0035] and [@bib0140]                                                                                                                                                                                                                                                                             
  **(Arg713Trp)\***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Leu1549Met (Leu1527Met)\*    No influence on FH, MCP, or CR1 binding                                                                                                                                                                                                                                                                                                                                                                  [@bib0395]                                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  *C9*                         **Arg95Ter**                                                                                                                                                                                                                                                                                                                                                                                             C9 serum concentration was below the level of detection                                                                                                                                                                                                                                               [@bib0160] and [@bib0210]

  **Pro167Ser**                Median C9 serum concentration was elevated in carriers compared to non-carriers                                                                                                                                                                                                                                                                                                                          [@bib0165]                                                                                                                                                                                                                                                                                            
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Only variants on which functional analysis were done are shown. \*described in literature without signaling peptide. Bold: genetic association with AMD through case-control analysis or found in multiple cases of within an AMD family.

###### 

Clinical trials for AMD targeting the complement system.

Table 4

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug, trade name (company)                          Target                   Status                                                                              Source
  --------------------------------------------------- ------------------------ ----------------------------------------------------------------------------------- ------------------------------------------------------------
  Eculizumab, Soliris (Alexion)                       Complement component 5   Phase II has been completed                                                         [@bib0505]

  Lampalizumab (Genentech, Roche)                     Complement factor D      Phase II has been completed; recruitment for phase III clinical trial has started   [@bib0375] and [@bib0475]

  Avacincaptad pegol (ARC-1905) Zimura (Ophthotech)   Complement\              Recruitment for II/III clinical trial has started.                                  [Clinicaltrials.gov](http://Clinicaltrials.gov){#intr0005}
                                                      component 5                                                                                                  

  Tesidolumab, LFG316 (Novartis)                      Complement\              Recruitment for II/III clinical trial has started                                   [Clinicaltrials.gov](http://Clinicaltrials.gov){#intr0010}
                                                      component 5                                                                                                  

  CLG561 (Novartis)                                   Properdin                Recruitment for phase II clinical trial has started                                 [Clinicaltrials.gov](http://Clinicaltrials.gov){#intr0015}

  POT4, (Potentia Pharmaceuticals and Alcon)          Complement\              Phase I has been completed.                                                         [Clinicaltrials.gov](http://Clinicaltrials.gov){#intr0020}
                                                      component 3                                                                                                  
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
